Isomorphic Labs, led by Alphabet co-founder Demis Hassabis, raised $2.1 billion in a Series B round led by Thrive Capital, with participation from Alphabet, GV, MGX, Temasek, CapitalG, and the UK Sovereign AI Fund.
The company's IsoDDE platform combines multiple proprietary AI models designed to work across different therapeutic areas and drug classes. The funding will expand the platform, advance drug candidates closer to clinical trials, and support global hiring.
Isomorphic Labs was founded in London in 2021 and has existing partnerships with Novartis, Lilly, and Johnson & Johnson.
Summaries like this, in your inbox every morning.
Pick your industry and the AI tools you use, and get news related to your work every day.
Free · 30 seconds with Google · unsubscribe anytimeWhat is AIToday? →
Ask AI anything about this article. The AI reads this article, earlier AIToday articles, and Wikipedia, and cites its sources. Q&As are published on this page for other readers too.
Hewlett Packard Enterprise stock is down 5% at $55.87
The Motley Fool argues Amazon is the AI company of the two, since AWS was just 21% of first-half 2026 revenue…
Vercel data published Thursday shows TypeSafe AI's Jev, a lightweight decision model for choosing among predet…
Chunghwa Telecom president Rong-shy Lin said the shift from conversational AI to autonomous AI agents is resha…
CoreWeave fell 5% in premarket trading Friday and was on track to finish the week down 15%, after rebounding f…
Apple and Meta said they would jointly release a new open-weight AI model designed to run on high-end Macs, ai…
